ScreenerHero

ARTVArtiva Biotherapeutics Inc. Common Stock

NAS · US · Healthcare · Biotechnology · artivabio.com
10.93USD-6.58%Mkt Cap: 534.37M $P/E: —

Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. Its lead product candidate…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap534.37M $
Enterprise Value205.09M $
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-83.86M $
Revenue/Share—
Last Price10.93 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees115
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-4.27
PEG—
EV/EBITDA-2.19
EV/Revenue—
P/S—
P/B1.56
EPS (TTM)-3.08
EPS (Forward)-2.61
52W Range
2.22071% of range14.53
52W High14.53 USD
52W Low2.220 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-76.26%
ROA-64.05%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-76.75M $
CapEx (TTM)2.59M $
FCF Margin—
FCF Yield-8.31%
Net Debt-339.54M $
Net Debt/EBITDA3.63
Balance Sheet
Debt/Equity0.10
Current Ratio24.16
Quick Ratio24.06
Book Value/Sh7.122 USD
Cash/Share7.147 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.2 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)35.80 USD
Upside (mean)+227.5%
Target Range23.00 USD – 41.00 USD
$23.00+227.5% to mean$41.00
# Analysts5
Ownership
Shares Out.48.89M
Float21.35M
Insiders14.89%
Institutions84.05%
Short Interest
Short Ratio4.6d
Short % Float5.60%
Short % Out.3.93%
Shares Short1.92M
Short (prev mo.)1.34M
Technical
SMA 5010.04 (+8.8%)
SMA 2006.976 (+56.7%)
Beta2.18
S&P 52W Chg18.16%
Avg Vol (30d)363.81K
Avg Vol (10d)297.02K
Technical Indicators
RSI (14)52.0
MACD0.4694
MACD Signal0.5071
MACD Hist.-0.0376
BB Upper12.24 USD
BB Middle10.97 USD
BB Lower9.713 USD
BB Width22.99%
ATR (14)0.8289 USD
Vol Ratio (20d)0.57x